OPGEN Pivots to FinTech, Faces Nasdaq Delisting Amidst Revenue Collapse

TL;DR

**OPGEN's complete business model overhaul and Nasdaq delisting signal extreme volatility; stay away until a clear, profitable path emerges in its new FinTech venture.**

AI Summary

OPGEN INC (OPGN) reported a significant shift in its business model and financial performance for the three months ended March 31, 2025. The company recorded zero revenue from product sales and laboratory services, a sharp decline from $141,373 and $26,776, respectively, in the same period of 2024. This change reflects its strategic pivot from precision medicine to financial services and technology. The net loss for the quarter was $408,133, a substantial reversal from a net income of $287,967 in Q1 2024. General and administrative expenses decreased significantly to $513,344 from $1,684,151 year-over-year, while sales and marketing expenses also dropped to $9,502 from $128,646. Cash and cash equivalents stood at $1,112,781 as of March 31, 2025, down from $1,310,653 at December 31, 2024. The company has access to an additional $7.0 million through a Securities Purchase Agreement with AEI Capital Ltd. until December 31, 2025, which management believes will fund operations for over 12 months. However, OPGN faces delisting from Nasdaq due to non-compliance with the minimum stockholders' equity requirement of $2,500,000, with its stockholders' equity at $7,054,203 as of March 31, 2025, but the Nasdaq Panel denied its request for continued listing.

Why It Matters

OPGEN's dramatic pivot from precision medicine to financial services and technology, specifically listing sponsorship and digital investment banking, represents a high-risk, high-reward strategy for investors. The complete cessation of legacy revenue streams and a net loss of $408,133 in Q1 2025 highlight the challenges of this transition. For employees, this means a complete restructuring of roles and skills. Customers of its former precision medicine solutions will need to find new providers. The competitive landscape in financial technology is fierce, and OPGN, with its history in biotech, enters as an unproven player, making its ability to gain market share and generate new revenue highly uncertain. The Nasdaq delisting further complicates its ability to attract capital and maintain investor confidence.

Risk Assessment

Risk Level: high — The risk level is high due to the complete cessation of revenue from its legacy business, reporting $0 in product sales and laboratory services for Q1 2025, down from $168,149 in Q1 2024. Furthermore, the company received a denial from the Nasdaq Hearings Panel for continued listing due to non-compliance with the $2,500,000 minimum stockholders' equity rule, despite having $7,054,203 in stockholders' equity as of March 31, 2025, indicating significant operational and market confidence issues.

Analyst Insight

Investors should exercise extreme caution and consider divesting any existing positions in OPGN. The company's complete business model pivot and imminent Nasdaq delisting introduce substantial uncertainty and risk. Wait for clear evidence of sustained revenue generation and profitability in its new financial services and technology segment before considering any investment.

Financial Highlights

debt To Equity

0.33

revenue

$0

operating Margin

N/A

total Assets

$9,418,517

total Debt

$2,364,314

net Income

$(408,133)

eps

N/A

gross Margin

N/A

cash Position

$1,112,781

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $0 — Total Revenue (for Q1 2025, down from $168,149 in Q1 2024, reflecting business model shift.)
• $(408,133) — Net Loss (for Q1 2025, compared to net income of $287,967 in Q1 2024.)
• $1,112,781 — Cash and Cash Equivalents (as of March 31, 2025, a decrease from $1,310,653 at December 31, 2024.)
• $7,054,203 — Total Stockholders' Equity (as of March 31, 2025, above Nasdaq's $2,500,000 minimum, yet delisting denied.)
• $7.0 million — Available Financing (from AEI Capital Ltd. until December 31, 2025, for operational funding.)
• $513,344 — General and Administrative Expenses (for Q1 2025, a significant reduction from $1,684,151 in Q1 2024.)
• 10,071,286 — Common Stock Shares Outstanding (as of October 1, 2025, reflecting recent issuances.)

Key Players & Entities

• OPGEN INC (company) — registrant
• Curetis N.V. (company) — former business combination partner
• Curetis GmbH (company) — former subsidiary that filed for insolvency
• Ares Genetics GmbH (company) — former wholly-owned subsidiary that filed for insolvency
• David E. Lazar (person) — former CEO, Chairman, and Director; current President
• AEI Capital Ltd. (company) — significant investor and financing partner
• CapForce International Holdings Ltd. (company) — wholly-owned subsidiary for new business line
• Nasdaq Capital Market (regulator) — exchange where OPGN was listed and faces delisting
• $1,112,781 (dollar_amount) — cash and cash equivalents as of March 31, 2025
• $7.0 million (dollar_amount) — additional common stock OPGN can sell to AEI Capital Ltd.

FAQ

Risk Factors

• Nasdaq Delisting Risk [high — regulatory]: OPGN faces delisting from Nasdaq due to non-compliance with minimum stockholders' equity requirements. Despite having $7,054,203 in stockholders' equity as of March 31, 2025, the Nasdaq Panel denied its request for continued listing, posing a significant risk to liquidity and investor confidence.
• Business Model Transition Uncertainty [high — financial]: The company has undergone a significant pivot from precision medicine to financial services and technology. This transition resulted in zero revenue from product sales and laboratory services in Q1 2025, creating substantial uncertainty about future revenue generation and profitability.
• Cash Burn and Funding Dependency [medium — financial]: Cash and cash equivalents decreased to $1,112,781 as of March 31, 2025. While the company has access to $7.0 million through a Securities Purchase Agreement, this funding is critical for operations for over 12 months, highlighting a dependency on external financing and potential cash flow challenges.
• Reduced Operational Expenses [medium — operational]: General and administrative expenses decreased significantly to $513,344 in Q1 2025 from $1,684,151 in Q1 2024, and sales and marketing expenses dropped to $9,502 from $128,646. While this improves near-term cash burn, it may also reflect reduced operational capacity or investment in the new business model.
• Unregistered Sales of Equity Securities [low — legal]: The filing mentions 'Unregistered Sales of Equity Securities' as a risk factor. This could indicate potential legal or regulatory scrutiny if not properly managed, impacting investor perception and future capital raising efforts.
• Defaults Upon Senior Securities [high — legal]: The mention of 'Defaults Upon Senior Securities' as a risk factor suggests potential financial distress or covenant breaches, which could lead to significant financial penalties or forced restructuring.

Industry Context

The company's pivot from precision medicine to financial services and technology places it in a highly competitive and rapidly evolving landscape. The financial services sector is characterized by established players and disruptive fintech startups, while the technology sector demands continuous innovation and significant R&D investment. Success will depend on OPGN's ability to establish a strong market position and differentiate its offerings in these new domains.

Regulatory Implications

The most immediate regulatory concern is OPGN's delisting from Nasdaq. This non-compliance with listing standards, despite current equity levels, poses a significant risk. The company must navigate potential alternative listing venues or private market operations, which could impact liquidity and investor access.

What Investors Should Do

1. Monitor the success of the new business model
2. Assess the sustainability of funding
3. Evaluate the impact of Nasdaq delisting
4. Analyze expense management

Key Dates

• 2025-03-31: End of Q1 2025 — Reported zero revenue, a net loss of $408,133, and cash and cash equivalents of $1,112,781. Stockholders' equity stood at $7,054,203.
• 2025-12-31: Securities Purchase Agreement Expiration — The $7.0 million financing facility from AEI Capital Ltd. is available until this date, crucial for funding operations.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (OPGN has a significant accumulated deficit of $(293,908,655) as of March 31, 2025, reflecting its history of losses, which is a key factor in its financial condition.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. It represents capital contributed by investors in excess of the nominal value of the shares. (OPGN has substantial additional paid-in capital of $300,862,143, indicating significant past equity issuances, even with a large accumulated deficit.)

Operating lease right-of-use assets

Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (These assets, totaling $817,377, are part of OPGN's balance sheet and are related to its lease obligations.)

Intangible assets, net

Non-physical assets that have value, such as patents, trademarks, or goodwill, net of amortization. (The appearance of $12,500 in intangible assets in Q1 2025 suggests new acquisitions or development in this area, potentially related to the new business strategy.)

Securities Purchase Agreement

A contract between a company and investors outlining the terms and conditions for the purchase of securities, often used for raising capital. (OPGN has a $7.0 million agreement with AEI Capital Ltd., which is critical for its ongoing operational funding.)

Year-Over-Year Comparison

Compared to the prior year's Q1 2024, OPGN has experienced a dramatic shift. Total revenue has fallen from $168,149 to $0, and the company has moved from a net income of $287,967 to a net loss of $408,133. Operating expenses have been significantly reduced, particularly general and administrative costs, which dropped from $1,684,151 to $513,344. Stockholders' equity remains above Nasdaq's minimum requirement, but the company faces delisting. Cash reserves have decreased from $1,310,653 at the end of 2024 to $1,112,781.

Key Financial Figures

• $0.01 — f the Company's common stock, par value $0.01 per share, were outstanding as of Octob
• $3.0 billion — pwide assets under management exceeding $3.0 billion (see Note 8). In conjunction with the t
• $1.1 — ompany has cash and cash equivalents of $1.1 1,112,781 million as of March 31, 2025.
• $3.0 million — tock having an aggregate value of up to $3.0 million. The purchase price for any shares sold

Filing Documents

• opgeninc_10q.htm (10-Q) — 733KB
• opgeninc_ex31-1.htm (EX-31.1) — 18KB
• opgeninc_ex32-1.htm (EX-32.1) — 8KB
• 0001829126-25-007819.txt ( ) — 4245KB
• opgn-20250331.xsd (EX-101.SCH) — 33KB
• opgn-20250331_cal.xml (EX-101.CAL) — 51KB
• opgn-20250331_def.xml (EX-101.DEF) — 149KB
• opgn-20250331_lab.xml (EX-101.LAB) — 259KB
• opgn-20250331_pre.xml (EX-101.PRE) — 220KB
• opgeninc_10q_htm.xml (XML) — 557KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27 PART II. OTHER INFORMATION 28 Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29

SIGNATURES

SIGNATURES 30 i INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this quarterly report, we refer to OpGen, Inc. as the "Company", "OpGen", "we", "our" or "us". All statements, other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words "believe", "may", "will", "estimate", "continue", "anticipate", "design", "intend", "expect" or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I Item 1A "Risk Factors" of our most recent annual report on Form 10-K. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our liquidity and working capital requirements, including our cash requirements over the next 12 months; our ability to execute upon and achieve the benefits of th

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements OpGen, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 1,112,781 $ 1,310,653 Accounts receivable, net 34,096 29,258 Prepaid expenses and other current assets 1,091,639 1,309,316 Total current assets 2,238,516 2,649,227 Property and equipment, net 1,041,593 1,079,275 Operating lease right-of-use assets 817,377 825,665 Investment in equity securities 5,000,000 5,000,000 Deferred offering costs 6,269 6,269 Intangible assets, net 12,500 - Restricted cash 302,262 302,262 Total assets $ 9,418,517 $ 9,862,698 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 311,637 $ 245,196 Accrued compensation and benefits 19,710 62,907 Accrued liabilities 51,539 62,074 Short-term insurance financing - 90,278 Current portion of operating lease liabilities 180,601 173,726 Total current liabilities 563,487 634,181 Operating lease liabilities, net of current portion 1,800,827 1,847,889 Total liabilities 2,364,314 2,482,070 Commitments and Contingencies (Note 9) Stockholders' equity: Series D Preferred stock, $ 0.01 par value; 10,000,000 shares authorized; 250 shares issued and outstanding at March 31, 2025 and December 31, 2024 2 2 Common stock, $ 0.01 par value; 100,000,000 shares authorized; 10,071,286 and 10,070,779 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 100,713 100,708 Additional paid-in capital 300,862,143 300,780,440 Accumulated deficit ( 293,908,655 ) ( 293,500,522 ) Total stockholders' equity 7,054,203 7,380,628 Total liabilities and stockholders' equity $ 9,418,517 $ 9,862,698 See accompanying notes to unaudited condensed consolidated financial statements. 1 O

View Full Filing

View this 10-Q filing on SEC EDGAR